Margins
Beauty R&D and Formulation Cost Accounting: Capitalize vs Expense in 2026
Under US GAAP ASC 730, almost all beauty R&D, including formulation, lab work, and pre-launch stability testing, is expensed as incurred. You cannot capitalize it to flatter EBITDA. The real lever is tracking formulation cost per launch so you know what each SKU cost to bring to market.
Key Takeaways
- ASC 730 requires you to expense R&D as incurred. Formulation, experimental lab work, and pre-launch stability testing are R&D and hit the P&L now, not the balance sheet.
- Beauty Health, the only pure beauty name that discloses R&D, reports just 1.87 percent of revenue. Most private beauty brands spend 1 to 4 percent but bury it in COGS or overhead.
- You cannot capitalize formulation cost to lift EBITDA. A quality-of-earnings team reverses aggressive capitalization, which directly lowers your valuation before a raise or sale.
- Section 174A (effective for tax years after Dec 31, 2024) restored immediate domestic R&E expensing. Book and tax now line up again for most US beauty brands.
- Track formulation cost per launch as a project code. It is the number that tells you whether a hero SKU earned its development spend.
Most beauty founders ask the wrong question about R&D. They want to know whether they can capitalize formulation work to make EBITDA look better. The answer is almost always no, and chasing that lever is a waste of energy. The question that actually moves your business is: what did each launch cost to develop, and is that spend visible anywhere in your numbers?
Right now it probably is not. The dollars are real (chemist time, sample batches, contract-lab invoices, stability chambers) but they are scattered across cost of goods sold and unallocated overhead. That makes your gross margin look messier than it is and hides whether your hero SKU earned its development cost. This post covers how to book formulation, lab, and stability-testing costs correctly under US GAAP, what the 2025 tax change did, and the one tracking habit that pays for itself.
The GAAP rule: expense it, almost always
Under US GAAP, the governing standard is ASC 730, Research and Development. The rule is blunt: R&D costs are recognized as an expense when incurred. The logic is that the future benefit of research is too uncertain to sit on the balance sheet, so it hits the P&L now.
For a beauty brand, the activities that count as R&D under ASC 730 include:
- Developing a new formula (a novel serum, an SPF, a color cosmetic with a new system)
- Experimental lab work to dial in concentration, texture, pH, and performance
- Screening new actives or delivery technologies
- Pre-launch stability and compatibility testing done to validate shelf life on a new formulation
All of that is expensed as incurred. The only thing you capitalize is equipment or materials with a genuine alternative future use (a lab mixer you will also use for QC, for example), and even then only the depreciation flows through R&D expense. This is consistent with how Eightx frames the broader lever in capitalize vs expense: the GAAP rules: ASC 730 is the baseline, and you only leave it when another Codification topic applies, which it rarely does for physical product formulation.
Stability testing: it depends on timing
The one place founders get the booking wrong is stability testing, because the same activity can be R&D or COGS depending on when it happens.
| Activity | Timing | Treatment |
|---|---|---|
| Stability and compatibility testing | Pre-launch, validating a new formula | R&D, expensed now |
| Stability and compatibility testing | New active or significant reformulation | R&D, expensed now |
| Batch-release stability checks | Existing SKU in production | Quality control, usually COGS |
| Routine shelf-life monitoring | Commercialized product | Quality control, usually COGS |
The test is whether the work is resolving uncertainty about a product you have not launched yet, or routinely confirming a product you already sell. The first is R&D. The second is the cost of running your supply chain and belongs in COGS, where it pulls down gross margin alongside product cost and freight. Getting this split right keeps your gross margin honest, which matters when you benchmark against the beauty ecommerce margin benchmarks where the public median sits at 69.4 percent and the private-brand median at 62 percent.
What beauty R&D actually looks like on public financials
Here is the uncomfortable truth: almost nobody discloses it. In the Eightx screen of 20 public DTC and CPG brands, only 5 separately report R&D on the income statement, a 25 percent disclosure rate. The rest fold product development into COGS or G&A, so the statement reads zero. The full cut is in the R&D percent of revenue benchmark.
Beauty Health, the only pure beauty name in the disclosing set, reports 1.87 percent of revenue, the same as the median across all five disclosers. Beyond Meat at 8.43 percent is the outlier because plant-based protein chemistry genuinely meets the GAAP research definition. For a typical beauty brand, formulation is product development, not scientific research, which is exactly why it gets embedded in COGS rather than broken out.
At private brands in the 5M to 50M range, the figure is functionally zero on the income statement even though the real spend runs 1 to 4 percent of revenue. The money exists. It is just invisible.
The EBITDA temptation, and why it is a trap
Founders preparing for a raise or sale sometimes ask whether capitalizing formulation costs would lift EBITDA. Mechanically, capitalizing qualifying costs can swing reported EBITDA margin by 100 to 300 basis points on 1 to 3 percent of revenue, because the spend moves off OpEx into a future amortization line that EBITDA ignores. Cash does not change at all.
The problem is twofold. First, beauty formulation does not qualify under ASC 730, so capitalizing it is not aggressive accounting, it is wrong accounting. Second, even where capitalization is technically allowed, a quality-of-earnings team in a transaction will reverse anything aggressive and adjust EBITDA right back down. You do not get credit for the spend you tried to hide, and you lose credibility in diligence. The valuation impact runs the wrong way.
The credit you actually want comes from making product-development investment visible and intentional, not from burying it in a balance-sheet line a buyer will unwind.
The 2025 tax change you should know about
Book treatment is one thing; tax is another. From 2022 through 2024, the Tax Cuts and Jobs Act forced you to capitalize and amortize research and experimental costs under IRC Section 174 (5 years domestic, 15 years foreign), even though GAAP kept expensing them. That created an annoying book-tax gap and real cash pain for brands doing formulation work.
The 2025 One Big Beautiful Bill Act added new IRC Section 174A, which restored immediate expensing of domestic R&E for tax years beginning after December 31, 2024. For most US beauty brands, book and tax now line up again: formulation work is expensed both places. Two caveats. Foreign R&E (say, a lab in another country) still amortizes over 15 years under Section 174. And eligible small businesses can amend 2022 to 2024 returns to claw back cash from the prior capitalization regime, which is worth checking with your tax advisor. Confirm specifics with the IRS and your CPA before filing.
What to do about it
- Stop trying to capitalize formulation. Under ASC 730 it gets expensed as incurred. Spend the energy on tracking instead.
- Open a project code per launch. Tag every chemist hour, sample-batch material, contract-lab invoice, and pre-launch stability test to that SKU. At launch, total it. That number is your formulation cost per launch.
- Split stability testing correctly. Pre-launch validation is R&D and expensed now. Routine monitoring of live SKUs is QC and belongs in COGS so your gross margin stays clean.
- Pull product development out of your COGS noise. Knowing how much sits inside COGS lets you read true gross margin against the beauty benchmarks and set price using a real cost base, the way we lay out in how to price beauty products.
- Budget formulation as part of launch working capital. Development spend hits cash months before first revenue, so fold it into the launch cash plan covered in beauty launch working capital.
- Check the Section 174A reversal. If you capitalized R&E in 2022 to 2024 and qualify as a small business, you may be able to amend and recover cash. Ask your CPA.
If you want a CFO to wire this into your books so product-development spend is visible and your margin is honest, that is exactly the kind of work our fractional CFO for beauty brands service handles.
Methodology
R&D intensity figures are drawn from the Eightx screen of 20 publicly-traded DTC and CPG brands, of which 5 separately disclose R&D, sourced from the latest 10-K filings on SEC EDGAR and summarized in the R&D percent of revenue benchmark. Margin reference points come from the beauty ecommerce margin benchmarks. Accounting treatment reflects FASB ASC 730. Tax treatment reflects IRC Section 174 as amended by the Tax Cuts and Jobs Act and new Section 174A added by the 2025 One Big Beautiful Bill Act. None of this is tax or accounting advice for your specific situation; confirm with your CPA.
Frequently Asked Questions
can a beauty brand capitalize formulation costs under us gaap?
Generally no. Under ASC 730, new product formulation, experimental lab work, and pre-launch stability testing are R&D and must be expensed as incurred. Only equipment or materials with an alternative future use go on the balance sheet, and only their depreciation hits R&D expense.
is stability testing an r&d expense or cost of goods sold?
It depends on timing. Stability testing on a new or significantly reformulated product, done before launch to validate shelf life, is R&D and is expensed now. Routine batch-release or shelf-life monitoring on an existing SKU is quality control and usually sits in COGS.
how much do beauty brands spend on r&d as a percent of revenue?
Beauty Health, the only pure beauty brand that discloses it, reports 1.87 percent of revenue. Most private beauty brands at 5M to 50M spend roughly 1 to 4 percent on product development but bury it inside COGS or overhead, so the income statement reads near zero.
what is section 174a and does it affect my beauty brand?
Section 174A, added by the 2025 One Big Beautiful Bill Act, restored immediate expensing of domestic research costs for tax years beginning after Dec 31, 2024. For most US beauty brands this means book and tax treatment of formulation costs line up again. Foreign R&E still amortizes over 15 years.
does capitalizing r&d increase ebitda?
Capitalizing qualifying costs can lift reported EBITDA by 100 to 300 basis points on 1 to 3 percent of revenue, because the spend moves into a future amortization line EBITDA ignores. But beauty formulation rarely qualifies under GAAP, and a quality-of-earnings review reverses aggressive capitalization, dragging your valuation back down.
how do i track formulation cost per launch?
Open a project code per SKU launch and tag every chemist hour, lab consumable, contract-lab invoice, and pre-launch stability test to it. At launch, total the code. That is your formulation cost per launch, and it tells you whether the SKU earned its development spend.